Patents by Inventor Megumi Yoshikawa

Megumi Yoshikawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210164130
    Abstract: An acrylic fiber for artificial hair may include an acrylic copolymer. The acrylic fiber has a fiber cross section including 2 to 4 T-shaped protrusions that extend radially from a central portion. Each of the T-shaped protrusions has an arc-shaped upper side that bulges in a direction away from the central portion. A circumradius of the fiber cross section is 40.0 to 60.0 ?m. A distance between adjacent end portions of the corresponding upper sides of the adjacent T-shaped protrusions is 3.0 to 60.0 ?m. An axial width is 10.0 ?m or more. Torsional rigidity of the acrylic fiber is 0.30 to 2.0 mg·cm2. The acrylic fiber for artificial hair has high volume, good texture, and good twist processability, and a hair ornament may include the acrylic fiber for artificial hair.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 3, 2021
    Applicant: KANEKA CORPORATION
    Inventors: Megumi Yoshikawa, Takao Michinobu, Takeshi Tanaka
  • Patent number: 8003098
    Abstract: The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.
    Type: Grant
    Filed: February 22, 2007
    Date of Patent: August 23, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Shuichi Nakatsuru, Megumi Yoshikawa, Shinichi Hiroshima, Yoshiro Kishi, Motoki Kuhara, Shiyo Nishida, Midori Shinohara
  • Publication number: 20110137276
    Abstract: An absorbent article has a liquid permeable top sheet (5) making contact with the wearer's skin surface, a liquid impermeable back sheet (6) making contact with the surface of underwear, and an absorber (7) mounted between the top sheet (5) and the back sheet (6) and capable of absorbing a bodily liquid. The an absorber (7) has a projected portion (2) which is a portion formed on a lower layer absorber (8) by overlaying an upper layer absorber (9) on the lower layer absorber (8), and the upper layer absorber (9) has smaller dimensions in the longitudinal and lateral directions than the lower layer absorber (8). A first recessed portion (3) is provided around the projected portion (2) so as to surround the projected portion (2). The first recessed portion (3) is formed by a continued portion (3a) and an intermittent portion (4).
    Type: Application
    Filed: January 27, 2009
    Publication date: June 9, 2011
    Applicant: Uni-Charm Corporation
    Inventor: Megumi Yoshikawa
  • Patent number: 7786266
    Abstract: The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides methods and pharmaceutical compositions that comprise anti-DSC2 antibody as an active ingredient for damaging DSC2-expressing cells via the effector function of the antibody.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: August 31, 2010
    Assignee: Oncotherapy Science, Inc.
    Inventors: Shuichi Nakatsuru, Takashi Iwamoto, Megumi Yoshikawa
  • Publication number: 20090191211
    Abstract: The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.
    Type: Application
    Filed: February 22, 2007
    Publication date: July 30, 2009
    Applicant: Oncotherapy Science, Inc.
    Inventors: Shuichi Nakatsuru, Megumi Yoshikawa, Shinichi Hiroshima
  • Publication number: 20090169572
    Abstract: The present invention relates to the use of cytotoxicity based on the effector function of anti-CDH3 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient for damaging CDH3-expressing cells using antibody effector function. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.
    Type: Application
    Filed: February 28, 2007
    Publication date: July 2, 2009
    Applicant: Oncotherapy Science, Inc,
    Inventors: Shuichi Nakatsuru, Megumi Yoshikawa, Shinichi Hiroshima
  • Publication number: 20090155219
    Abstract: The present invention relates to the use of cytoxicity based on the effector function of anti-GFRA1 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-GFRA1 antibody as an active ingredient for damaging GFRA1-expressing cells using antibody effector function. Since GFRA1 is strongly expressed in breast, gastric, liver, renal or lung cancer cells, the present invention is useful in breast, gastric, liver, renal or lung cancer therapies.
    Type: Application
    Filed: March 11, 2005
    Publication date: June 18, 2009
    Applicant: ONCOTHERAPY SCIENCE, INC
    Inventors: Shuichi Nakatsuru, Takashi Iwamoto, Megumi Yoshikawa
  • Publication number: 20080260748
    Abstract: The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides methods and pharmaceutical compositions that comprise anti-DSC2 antibody as an active ingredient for damaging DSC2-expressing cells via the effector function of the antibody.
    Type: Application
    Filed: May 11, 2006
    Publication date: October 23, 2008
    Applicant: Oncotherapy Science, Inc.
    Inventors: Takashi Iwamoto, Megumi Yoshikawa
  • Patent number: 5926519
    Abstract: This invention relates to the structure of multiple registers used in image signal processing, and aims to simplify the register structure and to reduce the power consumption of the registers and the time required for testing an image signal processing LSI with the registers. A semiconductor integrated circuit according to the invention has a clock generation circuit and a clock buffer circuit for generating a plurality of clock signals, a register group including a plurality of registers connected in series and operable in synchronism with the clock signals, at least one combinational circuit connected to the register group, and means for selecting one of a normal operation mode and a scan test mode for the register group. The clock generation circuit receives a system clock CP.sub.IN, a scan test mode selection signal S.sub.MODEN, and clock CPS.sub.IN, and outputs a clock .phi. and a clock (.phi..sub.1 bar) controlled by the signal S.sub.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: July 20, 1999
    Assignee: Kabushiki Kaisha Toshiba
    Inventors: Megumi Yoshikawa, Yukinori Kudou